Proteomics International Laboratories Ltd
Company Profile
Business description
Proteomics International Laboratories Ltd is a biological research and drug discovery company. The company specializes in the area of proteomics which is the industrial-scale study of the structure and function of proteins. Its operations are divided into PromarkerD which targets the diabetes epidemic and is a predictive diagnostic test for diabetic kidney disease, a progressive disorder found in one in three adults with diabetes; its proprietary biomarker discovery platform called Promarker, which searches for protein fingerprints in a sample; and Analytical Services that are specialist contract research focusing on biosimilars quality control and pharmacokinetic testing for clinical trials.
Contact
6 Verdun Street
QEII Medical Centre, QQ Block
Nedlands
PerthWA6009
AUST: +61 893891992
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
Proteomics International Laboratories Ltd News & Analysis
funds
Proteomics set for growth, says Kardinia
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,946.20 | 20.00 | 0.22% |
| CAC 40 | 7,798.22 | 24.45 | -0.31% |
| DAX 40 | 24,307.80 | 18.29 | 0.08% |
| Dow JONES (US) | 44,323.07 | 19.12 | -0.04% |
| FTSE 100 | 9,012.99 | 20.87 | 0.23% |
| HKSE | 25,014.60 | 20.46 | 0.08% |
| NASDAQ | 20,974.18 | 78.52 | 0.38% |
| Nikkei 225 | 39,902.05 | 82.94 | 0.21% |
| NZX 50 Index | 12,831.27 | 130.24 | -1.00% |
| S&P 500 | 6,305.60 | 8.81 | 0.14% |
| S&P/ASX 200 | 8,684.60 | 16.40 | 0.19% |
| SSE Composite Index | 3,559.17 | 0.62 | -0.02% |